

Peptide-Based Hematological Disorders Therapeutics Market to Grow at 8.1% CAGR, Reaching US\$ 1,253.9 Million by 2034

Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeutics, says Fact.MR.

ROCKVILLE , MD, UNITED STATES,
December 13, 2024 /

EINPresswire.com/ -- According to Fact.MR, a market research and competitive intelligence provider, the global [peptide based hematological disorders therapeutics market](#) is

estimated to reach a valuation of US\$ 575.5 million in 2024 and is expected to grow at a CAGR of 8.1% during the forecast period of (2024 to 2034).



For several years, peptide-based therapeutics have emerged as the most powerful and selective therapeutic agents that effectively target cellular mechanisms with fewer side effects than ordinary small-molecule drugs. Peptide-based therapies, uniquely, can be engineered to modulate biological processes involved in hematopoiesis and immune response regulation with increased precision. Peptide synthesis, conjugation, and drug delivery systems technologies have seen progressive developments, which have improved the stability, bioavailability, and half-life of peptide drugs. The resulting maturity of the whole ushered in a slew of bright and effective treatment options in hematological disorders such as hemophilia, sickle cell anemia, leukemia, and lymphoma.

In addition, advances in peptide libraries and computational biology have enabled screening and identification of therapeutic peptides more efficiently, which have reduced timelines and costs for R&D. Adoption of artificial intelligence and machine learning in the whole process of peptide drug development is going to boost capabilities within the area. These breakthroughs in the technologies have also filled the market niche in terms of launch to create next-generation peptide therapeutics with elevated precision and efficacy.

For More Insights into the Market, Request a Sample of this Report:

https://www.factmr.com/connectus/sample?flag=S&rep_id=189

Key Takeaways from Market Study

The Global Peptide Based Hematological Disorders Therapeutics Market is projected to grow at 1% CAGR and reach US\$ 1,253.9 million by 2034

The market created an absolute \$ opportunity of US\$ 678.5 million growing at a CAGR of 1% between 2024 to 2034

North America is a prominent region that is estimated to hold a market share of 1% in 2034. Amgen, Inc., Johnson & Johnson (Janssen Pharmaceuticals), Roche (Chugai Pharmaceutical), Novartis AG, Sanofi S.A., Pfizer, Inc., Takeda Pharmaceutical Company, Eli Lilly and Company, Biogen, Inc., GlaxoSmithKline (GSK), Bristol Myers Squibb Company, AbbVie Inc., Merck & Co., Inc., AstraZeneca, and Alexion Pharmaceuticals (AstraZeneca subsidiary)

Thrombopoietin Receptor Agonists (TRAs) are estimated to grow at a CAGR of 2% creating an absolute \$ opportunity of US\$ 231.1 million between 2024 and 2034

North America and Western Europe are expected to create an absolute \$ opportunity of US\$ 418.3 million collectively

“Growing Prevalence of Hematological Disorders and Unmet Medical Needs will drive the Market” says a Fact.MR analyst.

Market Development

Increasing global prevalence of hematological disorders, such as hemophilia, anemia, thalassemia, and a wide range of blood cancers, will support the peptide therapeutics market. The conditions are often challenging to treat since available therapeutic options are ineffective for some, if not many, patients or have side effects. Hematological disorders often have high morbidity and mortality rates, further reinforcing the fact that novel treatments are needed. For instance, leukemia and lymphoma do not respond well to conventional therapies, which makes peptide therapeutics attractive due to their ability to really focus on only cancer cells, leaving healthy ones relatively unharmed. Likewise, genetic conditions like sickle cell disease or hemophilia could pursue highly specific treatments, one being available through peptide therapeutics.

In this area, numerous unmet medical needs remain, with a growing demand for therapies capable of treating rare and life-threatening blood disorders. Peptides represent an alternative to other types of therapy, potentially capable of a major intellectual leap in the treatment scenery. Hence, keeping in view the growing cohort of patient populations, the development of peptide-based drugs cannot be ruled out.

Growth Drivers for Peptide-Based Hematological Disorders Therapeutics Market

Increasing Prevalence of Hematological Disorders: The rising incidence of blood-related disorders, such as hemophilia, anemia, and thrombocytopenia, is driving the demand for peptide-based therapeutics as effective treatment options.

Advancements in Peptide Drug Development: Continuous innovations in peptide synthesis and delivery technologies are enabling the development of more effective, targeted, and stable peptide-based therapeutics for hematological conditions.

Focus on Precision Medicine: Growing emphasis on personalized healthcare is boosting the adoption of peptide-based therapies due to their ability to target specific biological pathways with minimal side effects.

Expanding Research and Development Efforts: Increased investment in R&D for peptide therapeutics by biopharmaceutical companies is fostering the discovery of novel drugs for hematological disorders.

Aging Population and Associated Disorders: The aging population, prone to blood disorders, is contributing significantly to the demand for advanced and efficient therapeutic solutions.

Regulatory Approvals and Clinical Success: Positive clinical outcomes and regulatory approvals of peptide-based therapeutics are accelerating their adoption in treating hematological disorders.

Get Customization on this Report for Specific Research Solutions:

https://www.factmr.com/connectus/sample?flag=S&rep_id=189

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the ambulance cot market, presenting historical demand data (2018 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights into the market based on product (emergency cots, transport cots), technology (manual cots, pneumatic cots, electric cots), and end user (EMS service providers, hospitals, ambulatory service centers), across six major regions of the world (North America, Europe, East Asia, Latin America, South Asia & Oceania, and MEA).

Checkout More Related Studies Published by Fact.MR Research:

[Peptide-based Cancer Therapeutics Market](#): Advancements in peptide-based cancer therapeutics, including innovations in drug delivery, stability, and modifications, are driving market growth by enabling effective treatment solutions for various cancers. These therapeutics offer targeted approaches with fewer side effects, addressing critical challenges in oncology.

[Peptide-based Cardiovascular Therapeutics Market](#): Innovations in peptide-based cardiovascular therapeutics, such as advancements in targeted therapies and enhanced effectiveness, are propelling market growth by tackling key challenges in heart disease treatment. These therapies

provide efficient solutions for cardiovascular conditions, enabling timely interventions and better patient outcomes.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:

11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States

S. N. Jha
Fact.MR
+1 628-251-1583
sales@factmr.com

This press release can be viewed online at: <https://www.einpresswire.com/article/768557411>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.